Compound Partnering

Compound partnering demonstrates PPD's ability to reduce development timelines by applying proven solutions leveraged from extensive global experience. We believe our success in compound partnering evolves from our effective contingency planning. Using our vast development experience, we are able to predict many potential outcomes and then address them in flexible contingency plans.

We also bridge steps in drug development by conducting early elements of a study while simultaneously planning for later phases. This strategic planning and use of best practices effectively speeds the process.

We are currently advancing several partnered programs.

Why Partner With PPD?

We look for compounds at pre-investigational new drug (IND) stage to Phase I stage with a straightforward, reasonably short development profile and a clear regulatory path.

In addition to experience with alliances and a track record of successful development programs, other reasons to partner with us include our innovative approach to development, a risk-sharing model that allows the innovator to preserve more value and our financial strength that gives us flexibility in our approach to structuring agreements. We also focus on understanding the culture of our partners and capitalizing on complementary strengths.

Venture Capital Investments

In addition to our compound partnering investments, we have invested in life sciences venture capital funds in order to access exciting early-stage technologies.